| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TEAD4 |
| Uniprot No | Q15561 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 74-434aa |
| 氨基酸序列 | MYGRNELIARYIKLRTGKTRTRKQVSSHIQVLARRKAREIQAKLKDQAAK DKALQSMAAMSSAQIISATAFHSSMALARGPGRPAVSGFWQGALPGQAGT SHDVKPFSQQTYAVQPPLPLPGFESPAGPAPSPSAPPAPPWQGRSVASSK LWMLEFSAFLEQQQDPDTYNKHLFVHIGQSSPSYSDPYLEAVDIRQIYDK FPEKKGGLKDLFERGPSNAFFLVKFWADLNTNIEDEGSSFYGVSSQYESP ENMIITCSTKVCSFGKQVVEKVETEYARYENGHYSYRIHRSPLCEYMINF IHKLKHLPEKYMMNSVLENFTILQVVTNRDTQETLLCIAYVFEVSASEHG AQHHIYRLVKE |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TEAD4重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Structural basis of YAP recognition by TEAD4 in the Hippo pathway*
**作者**: Chen L. et al.
**摘要**: 该研究解析了TEAD4重组蛋白与转录共激活因子YAP的复合物晶体结构，揭示了二者结合的关键结构域和相互作用机制，为靶向Hippo通路的药物设计提供了依据。
---
2. **文献名称**: *Recombinant TEAD4 DNA-binding domain characterization and its interaction with VGLL coactivators*
**作者**: Pobbati A.V. et al.
**摘要**: 作者通过大肠杆菌表达系统纯化重组TEAD4的DNA结合结构域，并利用生物物理手段(如ITC和SPR)验证其与VGLL蛋白的结合特异性，阐明了TEAD4调控靶基因的分子基础。
---
3. **文献名称**: *Development of covalent inhibitors targeting TEAD4 palmitoylation in cancer*
**作者**: Bum-Erdene K. et al.
**摘要**: 研究利用重组TEAD4蛋白筛选小分子库，发现一类共价抑制剂可通过阻断TEAD4的棕榈酰化修饰抑制其转录活性，为癌症治疗提供了新型候选化合物。
---
4. **文献名称**: *TEAD4 promotes cell proliferation by regulating core cell cycle genes in triple-negative breast cancer*
**作者**: Zhou Y. et al.
**摘要**: 通过体外重组TEAD4蛋白实验，证明其直接结合细胞周期相关基因(如CCND1、CDK6)的启动子区域，激活转录并促进三阴性乳腺癌细胞的异常增殖。
---
这些文献涵盖了TEAD4重组蛋白在结构生物学、分子互作、药物开发及肿瘤机制中的研究，可根据需求进一步扩展。
TEAD4 (Transcriptional Enhanced Associate Domain 4) is a member of the TEAD family of transcription factors, which play critical roles in regulating gene expression during development, tissue homeostasis, and cancer progression. TEAD proteins bind to DNA through a conserved TEA/ATTS DNA-binding domain and require co-activators, such as YAP (Yes-associated protein) or TAZ (Transcriptional co-activator with PDZ-binding motif), to modulate transcriptional activity. TEAD4. specifically, is involved in the Hippo signaling pathway, a key regulator of organ size, cell proliferation, and apoptosis. Dysregulation of TEAD4-YAP/TAZ interactions is frequently observed in cancers, including breast, lung, and colorectal malignancies, making it a target for therapeutic intervention.
Recombinant TEAD4 protein is engineered through molecular cloning and expressed in heterologous systems (e.g., E. coli, insect, or mammalian cells) to produce purified, functional protein for research. It typically retains the DNA-binding domain and other functional regions necessary for studying its interactions with co-activators or inhibitors. Recombinant TEAD4 is widely used in biochemical assays (e.g., electrophoretic mobility shift assays), structural studies (e.g., X-ray crystallography or cryo-EM), and high-throughput drug screening to identify compounds that disrupt TEAD-YAP/TAZ binding. Its production enables mechanistic insights into how post-translational modifications (e.g., palmitoylation) or mutations affect transcriptional regulation. Recent studies also leverage recombinant TEAD4 to develop targeted cancer therapies, such as small-molecule inhibitors or peptide-based disruptors, highlighting its biomedical relevance. Overall, recombinant TEAD4 serves as a vital tool for deciphering Hippo pathway dynamics and advancing precision oncology.
×
